Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Abbott Laboratories, Q3 2009 (Qtr End 09/30/09) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. Our first question today is from Frederick Wise - Leerink Swann, LLC. Frederick Wise - Leerink Swann, LLC Excellent quarter. Just trying to understand a little better, gross margin, if you could start with that, tell me if I understand...
- Earnings calls 2009-10-14
Additional Resources
- Abbott Profit Up on Humira Demand, Special Gain
- By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Abbott Laboratories Inc ABT said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc MDT. The profit reported on Wednesday topped Wall...
- News items 2009-10-14
- Abbott Labs Fires Agency That Screwed Up Humira Ads
- Abbott Labs has put its $70 million Humira ad account in review. The review follows a warning letter from the FDA about Humira's advertising, which the government called "misleading." The incumbent agency on the business is Harrison & Star, according to Adweek. The shop has had Humira since 2005, per...
- Blog posts 2009-03-05
- Arthritis drug holds key to Abbott uptick.(Annual Meetings)(Abbott Laboratories' new rheumatoid arthritis drug, Humira)
- Byline: SARAH A. KLEIN Abbott Laboratories is counting on its blockbuster rheumatoid arthritis drug Humira and a hoped-for full-scale reopening of its Lake County manufacturing plant to bridge a dry spell in its drug development efforts during the Byline: SARAH A. KLEIN ...
- Research articles 2003-05-05
- Can Abbott restock its cabinet? Humira is a bona fide hit, but the company's drug pipeline is drying up.(Abbott Laboratories Inc.)
- Byline: mike colias Abbott Laboratories' blockbuster rheumatoid arthritis drug Humira helps tens of thousands of victims of the debilitating disease, but it can't prop up the drugmaker's earnings forever. In just three years on the market, the t Byline: mike colias...
- Research articles 2006-05-29
- ABBOTT Laboratories. (Active Pharmaceutical Ingredient Watch).(boost price for Humira drug)(Brief Article)
- ABBOTT Laboratories raised its 2003 sales guidance for rheumatoid arthritis drug Humira ... ABBOTT Laboratories raised its 2003 sales guidance for rheumatoid arthritis drug Humira adalimumab by $50 million to $250 million. Guidance for 2004 remains unchanged at over $500 million.
- Research articles 2003-06-09
- Abbott delays pay raises to finance Humira launch
- Abbott Laboratories is preparing a program that will provide its new rheumatoid arthritis drug Humira free to eligible Medicare recipients lacking the necessary drug coverage. In internal communications to employees, Abbott Laboratories noted that it will delay salary increases in an effort to fund the cost of the Humira...
- Research articles 2003-03-01
- Stratagene to Realize Net Income of Approximately $14.6 Million from Settlement of Revenue Rights for Humira® Product Sales by Abbott
- LA JOLLA, Calif. -- Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced today that a settlement has been reached regarding monies due from Abbott Laboratories to Cambridge Antibody Technology (LSE:CAT)(Nasdaq:CATG) ("CAT") with respect to consideration due on sales of Humira R....
- Research articles 2005-10-26
- Abbott Seeks Expanded Approval on Humira and Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference.
- M2 PRESSWIRE-8 September 2006-U.S. Equity News: Abbott Seeks Expanded Approval on Humira and Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care ConferenceC1994-2006 M2 COMMUNICATIONS LTD RDATE:08092006 City of Industry, CA - Pharmaceuticals Instruments industry alert ...
- Research articles 2006-09-08
- At main plant, flexibility is the best medicine: the plant at Abbott's headquarters has adaptability that helped when it was called on to package the Humira Pen
- Versatility is one of the biggest imperatives at the main production facility at Abbott's headquarters. In Building AP 16 on Abbott's sprawling headquarters campus in far north suburban Chicago, 250,000 square feet is devoted to producing and packaging medicine, with 11 packaging lines that are able to handle many...
- Research articles 2006-12-01
- Shooting the messenger: new drugs target TNF-[alpha]: anti-TNF drugs Remicade, Enbrel and Humira may soon be joined by competitors both large and small.(Focus 2003: pharmaceutical leaders, CEOs and companies)
- Originally recognized for its effect on solid tumors, tumor necrosis factor-alpha, or TNF-[alpha], has been implicated in conditions as diverse as fever, anorexia, cardiovascular shock and colitis, but its widest renown may stem from its role as target for a growing class of disease-modifying anti-inflammatory drugs....
- Research articles 2003-09-29
- Why J&J's $1.7B Win in Abbott Humira Case May be Garbage
- Abbott Labs' management is probably not worrying too much about the $1.7 billion damages award made in favor of Johnson & Johnson's Centocor unit for Humira's infringment on the latter's Remicade patents. That's because the court that awarded the damages is a famous judicial hellhole known for favoring plaintiffs. by...
- Blog posts 2009-06-30
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- Need to know: Currency... COSCO... Rio Tinto
- View video and Need to Know interactive heatmap Economics Currency markets: The dollar rose yesterday and was heading for its first yearly gain against the euro since 2005 as the worst financial crisis in 80 years led investors to take refuge in the greenback. During morning trading in New York,...
- News items 2009-08-07
- Johnson & Johnson. (Active Pharmaceutical Ingredient Watch).(Brief Article)
- JOHNSON & JOHNSON'S Remicade infliximab, Abbott Laboratories' Humira adalimumab, and Amgen Inc.'s Enbrel etanercept were the subject of an FDA arthritis panel meeting last week. "As ... JOHNSON & JOHNSON'S Remicade infliximab, Abbott Laboratories' Humira adalimumab, and Amgen Inc.'s Enbrel etanercept were...
- Research articles 2003-03-10
- CAMBRIDGE ANTIBODY TECHNOLOGY (CAT).
- 678p - Pharmaceuticals - Cambridge Antibody Technology CAT stands out among the UK's biotechnology companies for one big reason: it is the first British biotech company to have a blockbuster product on the market. Humira, the company's antibody dru 678p - Pharmaceuticals - Cambridge Antibody Technology...
- Research articles 2006-02-24
- Abbott Laboratories Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question today is from Mike Weinstein. And please state your company name. Mike Weinstein - J.P. Morgan Thank you. It's J.P. Morgan. Excuse me, a couple questions if we could start-off. There was during this quarter, there was that Barron's article and there...
- Earnings calls 2007-07-18
- Analyst face-off: Abbott Labs
- NEW YORK Fortune -- Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion. Over the past few years, investors have cheered on Abbott, a $26 billion health care...
- News items 2009-08-07
- Anti-TNF alpha market appears poised for major growth. (Pharmaceuticals & Fine Chemicals).(Abbott Laboratories' Humira, Amgen's Enbrel )
- SEVERAL KEY developments in the past month have cracked open the market for anti-TNF tumor necrosis factor alpha therapies, a category with significant growth potential in the treatment of rheumatoid arthritis RA and other indications. Competit SEVERAL KEY developments in the past month have...
- Research articles 2003-01-13
- Abbott Laboratories
- Abbott Laboratories has opened a manufacturing plant in Barceloneta, Puerto Rico. The $450 million, 330,000-square-foot facility will produce Humira, its medicine for autoimmune disorders, and other biologics.
- Research articles 2007-06-01
- << Previous
- page 1 of 1
- Next >>
